CD74-ROS1 is the most common ROS1 fusion partner in NSCLC (~40-50% of ROS1+ cases) and as...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ROS1-CD74-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-ROS1-FUSION |
|---|---|
| Variant | CD74-ROS1 fusion |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | repotrectinib monotherapy, entrectinib monotherapy, crizotinib monotherapy |
| Evidence summary | CD74-ROS1 is the most common ROS1 fusion partner in NSCLC (~40-50% of ROS1+ cases) and associates with higher rates of brain metastases at diagnosis. Treated identically to other ROS1 fusions: entrectinib, repotrectinib, or crizotinib 1L. |
Notes
ESCAT IA. CD74-ROS1 specifically linked to higher CNS dissemination — bias toward CNS-active TKI (entrectinib, repotrectinib) over crizotinib.
Used By
No reverse references found in the YAML corpus.